Trial Profile
An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
- Indications Chickenpox; Hepatitis A; Hepatitis B; Influenza virus infections; Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 05 Nov 2019 Results published in the Pediatric Infectious Disease Journal
- 15 Oct 2018 Results published in the Pediatric Infectious Disease Journal
- 06 Mar 2018 Primary endpoint of First occurrence of RT-PCR confirmed influenza A and/or B disease of any severity due to any seasonal influenza strain has been met, according to a GlaxoSmithKline media release.